Scienture Holdings, Inc. (Nasdaq: SCNX), an SEC filer in Pharmaceutical Preparations, closed at $0.39, +3.7%, on 2026-08-28, with a market cap of $16M as of 2026-08-27, a return on equity of -55.6%, a net margin of -9618.0% and 3-year sales growth of -65.2%. Institutional ownership, earnings history and filed financials are on the tabs below.
No four consecutive quarters could be summed for EPS (Diluted), Revenue, Gross Profit; these figures use the latest fiscal year, not a trailing twelve months.
Some figures named '(TTM)' on this payload are the latest FISCAL YEAR, not a trailing twelve months — eps_ttm, gross_profit_ttm, revenue_ttm (fiscal year ended 2025-12-31). No four consecutive quarters could be summed for them — for an IFRS 20-F filer that is every income-statement line (no quarterly income statement is tagged to EDGAR at all); for a US filer it is usually one line the quarterly tagging skips. Each field's own basis is on field_basis.
full derived coverage requires a plan
Output of a disclosed model — assumptions may be wrong. Research, not investment advice. See the Disclaimer.
— Months · distinct values (the real sample size).
Metric
Today
Own median
Own range
%ile
z
Sector med.
mo · distinct
P/E (FY)
0.78×
only 2 monthly observations — under the 12-month floor for a series line. P/E and EPS growth are reconstructed for US-domestic 10-K filers only — a 20-F/40-F foreign private issuer's ADR trades in USD while its EPS is reported in the native currency, so no multiple is reconstructed rather than a wrong one.
−55.6%
−85.4%
no band (54 mo · 5 distinct)
—
—
−36.9%
54 · 5
ROIC (FY)
—
no reconstructed observations for this name and metric.
−9618.0%
−33.9%
5th
−2.38σ
−21.3%
66 · 6
−81.3%
−83.4%
no band (14 mo · 14 distinct)
—
—
5.1%
14 · 14
EPS Growth 3Y (FY)
—
P/E and EPS growth are reconstructed for US-domestic 10-K filers only — a 20-F/40-F foreign private issuer's ADR trades in USD while its EPS is reported in the native currency, so no multiple is reconstructed rather than a wrong one.
−65.2%
—
no band (29 mo · 3 distinct)
—
—
9.0%
29 · 3
Market Cap
$15.60M
not reconstructed — market cap was removed from the historical pass (never a ranking factor, and a reconstructed share count carries look-ahead risk). The single stored value is the forward-captured snapshot, not a series.
ROE (point-in-time)Health Care median, same monthshaded = own p10–p90 · dashed = own median · right-edge tick = today
shown for reference only — the reconstructed distribution did not clear the band gate, so no rank is quoted.
Multiple-implied price ladder · Full
Filed earnings only.
no P/E ladder — only 2 monthly observations — under the 12-month floor for a series line. P/E and EPS growth are reconstructed for US-domestic 10-K filers only — a 20-F/40-F foreign private issuer's ADR trades in USD while its EPS is reported in the native currency, so no multiple is reconstructed rather than a wrong one.
Ladder not drawn for this name — the reason is above.ⓘ
Not a forecast: each row re-prices today's filed earnings at a multiple this company itself once traded at. It abstains rather than guess on a loss year or a broken per-share basis.
Every month uses only what was filed by then, split-adjusted. Delisted names are absent and a trough year can throw one huge reading, so read the median, not the edges.
Percentile through time (point-in-time cohort)
Loading the monthly cohort placement…
▸Comp setname your own peers — pick a pool or add tickers
Covered pool$1.01T +7.3%/yr 2020→2025Concentration458 of 10,000fragmented · top 3 hold 22.1% · −50 pts since 2020SCNX0.0% · rank 333 of 364 · −0.0pp over 5y· CV 1.05 · σ 0.0pp
Who holds the poolCY2025 · bars scaled to the largest member
Growth, restated as sharewhere each pace has to END UP, by 2030
Its own realised pace0.0% → 0.0%
The pace the price requires— The growth today's price requires (our reverse-DCF) is a Pro metric — the realized-pace runway above is free.
SCNX share over time6 published years
Calendar year
2020
2021
2022
2023
2024
2025
Share of covered pool
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
coverage: 336 of the 385 members that…
Share of covered industry revenue · n=364 in Pharmaceuticals & Biotechnology · CY2025 pool · built 2026-08-29 not market shareⓘ
Covered filers only, not market share — private and uncovered companies are missing, so every share here reads high. Years are FX-converted and published only once most of the pool has filed.
